Randomized controlled trials often fail to capture what palliative care cannabis patients actually experience. A new contextual effectiveness framework argues that averaging subjective outcomes obscures genuine individual benefit. This Evidence Brief examines the dual-pathway model and what it means for clinical practice and guideline development